{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:22:37Z","timestamp":1791260557007,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.euroneuro.2023.04.003","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T17:21:51Z","timestamp":1683220911000},"page":"82-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Immunoinflammatory and oxidative alterations in subjects with schizophrenia under clozapine: A meta-analysis"],"prefix":"10.1016","volume":"73","author":[{"given":"Paulo Levi Bezerra","family":"Martins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2429-4341","authenticated-orcid":false,"given":"Ian Ara\u00fajo","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vit\u00f3ria Cristina Almeida Flexa","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa S.","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-9970","authenticated-orcid":false,"given":"Danielle S.","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel Porfirio","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.euroneuro.2023.04.003_bib0001","first-page":"200","article-title":"Serum TNF-\u03b1, IL-10 and IL-2 in schizophrenic patients before and after treatment with risperidone and clozapine","volume":"11","author":"Ajami","year":"2014","journal-title":"Iran. J. Immunol."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology","volume":"34","author":"Barnes","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.schres.2007.07.018","article-title":"Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study","volume":"97","author":"Byrne","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0004","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/j.amepre.2017.07.019","article-title":"Prevalence and medical costs of chronic diseases among adult medicaid beneficiaries","volume":"53","author":"Chapel","year":"2017","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0005","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4088\/JCP.15m10278","article-title":"The Economic Burden of Schizophrenia in the United States in 2013","volume":"77","author":"Cloutier","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0006","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"de Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02971","article-title":"Immune and neuroendocrine trait and state markers in psychotic illness: decreased kynurenines marking psychotic exacerbations","volume":"10","author":"de Picker","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0008","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1165\/ajrcmb.12.2.7865218","article-title":"Potent inhibition of both human interferon-gamma production and biologic activity by the Clara cell protein CC16","volume":"12","author":"Dierynck","year":"1995","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"Suppl 2","key":"10.1016\/j.euroneuro.2023.04.003_bib0009","article-title":"Cytokines as endogenous pyrogens","volume":"179","author":"Dinarello","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3233\/HAB-180344","article-title":"Serum cytokine profile in Schizophrenic patients","volume":"27","author":"Eftekharian","year":"2019","journal-title":"Hum. Antibodies"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0011","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/09629350123895","article-title":"Serum IL-1\u03b2, sIL-2R, IL-6, IL-8 and TNF-\u03b1 in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment","volume":"10","author":"Erba\u01e7ci","year":"2001","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0012","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/09629350123895","article-title":"Serum IL-1\u03b2, sIL-2R, IL-6, IL-8 and TNF-\u03b1 in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment","volume":"10","author":"Erba\u01e7ci","year":"2001","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0013","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","article-title":"A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000070012","article-title":"Decreased production of reactive oxygen species by blood monocytes caused by clozapine correlates with EEG slowing in schizophrenic patients","volume":"47","author":"Gross","year":"2003","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2010","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0016","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0924-977X(03)00042-7","article-title":"Toxic rise of clozapine plasma concentrations in relation to inflammation","volume":"13","author":"Haack","year":"2003","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0017","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1017\/S0033291704004118","article-title":"Mortality among patients with schizophrenia and reduced psychiatric hospital care","volume":"35","author":"Heil\u00e4","year":"2005","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0018","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.biopha.2018.04.109","article-title":"Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone","volume":"103","author":"Hendouei","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0019","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0893-133X(98)00006-2","article-title":"Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients","volume":"19","author":"Hinze-Selch","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0021","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0022","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/pcn.12508","article-title":"Role of cytokine changes in clozapine-induced fever: a cohort prospective study","volume":"71","author":"Hung","year":"2017","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0023","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"James","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0024","first-page":"905","article-title":"Panss, mental condition and inflammatory state of risperidone on schizophrenia","volume":"35","author":"Jin","year":"2019","journal-title":"Acta Med. Mediterr."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40273-016-0444-6","article-title":"The societal cost of schizophrenia: a systematic review","volume":"35","author":"Jin","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0026","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1099-1077(199806)13:4<231::AID-HUP976>3.0.CO;2-J","article-title":"Is there an association between the effects of clozapine on the production of reactive oxygen metabolites by blood monocytes and clinical outcome in neuroleptic-resistant schizophrenia?","volume":"13","author":"Joffe","year":"1998","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0027","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.psychres.2014.04.049","article-title":"Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine","volume":"218","author":"Klemettil\u00e4","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0028","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.psyneuen.2008.08.016","article-title":"Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever","volume":"34","author":"Kluge","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0029","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamapsychiatry.2018.2742","article-title":"Association of secondary preventive cardiovascular treatment after myocardial infarction with mortality among patients with schizophrenia","volume":"75","author":"Kugathasan","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.euroneuro.2022.03.001","article-title":"Precision psychiatry: the complexity of personalizing antipsychotic dosing","volume":"58","author":"Leon","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0031","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0920-9964(00)00094-3","article-title":"Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor","volume":"54","author":"Maes","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0032","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0920-9964(97)00057-1","article-title":"In vivo immunomodulatory effects of clozapine in schizophrenia","volume":"26","author":"Maes","year":"1997","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0033","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0447.1994.tb01527.x","article-title":"Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine","volume":"89","author":"Maes","year":"1994","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0034","doi-asserted-by":"crossref","DOI":"10.3390\/cells10112929","article-title":"First episode psychosis and schizophrenia are systemic neuro-immune disorders triggered by a biotic stimulus in individuals with reduced immune regulation and neuroprotection","volume":"10","author":"Maes","year":"2021","journal-title":"Cells"},{"issue":"69","key":"10.1016\/j.euroneuro.2023.04.003_bib0035","first-page":"4","article-title":"Prevention of suicide by clozapine in mental disorders: systematic review","volume":"12","author":"Masdrakis","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0036","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1007\/s12035-022-02889-1","article-title":"Interactions among brain-derived neurotrophic factor and neuroimmune pathways are key components of the major psychiatric disorders","volume":"59","author":"Mehterov","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0037","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.pnpbp.2009.11.024","article-title":"Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients","volume":"34","author":"Miljevic","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0038","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrd.2016.28","article-title":"Altering the course of schizophrenia: progress and perspectives","volume":"15","author":"Millan","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0039","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195687","article-title":"Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses","volume":"13","author":"Moreno-K\u00fcstner","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0041","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/15622975.2015.1062552","article-title":"High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance","volume":"16","author":"Noto","year":"2015","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0042","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.euroneuro.2018.12.008","article-title":"Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis","volume":"29","author":"Noto","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0043","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jpsychires.2018.04.019","article-title":"Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: a systematic review and meta-analysis","volume":"102","author":"Oakley","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2014.03.020","article-title":"Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine","volume":"156","author":"O'Connell","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0045","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s12035-019-01737-z","article-title":"The role of aberrations in the immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in different phenotypes of schizophrenia: the IRS-CIRS theory of schizophrenia","volume":"57","author":"Roomruangwong","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0046","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/nedt.1.2.171.61048","article-title":"Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication","volume":"1","author":"Schmitt","year":"2005","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0047","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0048","doi-asserted-by":"crossref","first-page":"I4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0049","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0920-9964(99)00116-4","article-title":"Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist","volume":"42","author":"Song","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/S0033291712002796","article-title":"Systematic review and collaborative recalculation of 133,693 incident cases of schizophrenia","volume":"44","author":"van der Werf","year":"2014","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0051","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1212\/WNL.45.6_Suppl_6.S6","article-title":"Cytokine production in the central nervous system","volume":"45","author":"Woodroofe","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2023.04.003_bib0052","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jpsychires.2012.04.026","article-title":"Elevated interleukin-18 serum levels in chronic schizophrenia: association with psychopathology","volume":"46","author":"Xiu","year":"2012","journal-title":"J. Psychiatr. Res."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2300072X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2300072X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:06:13Z","timestamp":1760378773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X2300072X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":52,"alternative-id":["S0924977X2300072X"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.04.003","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoinflammatory and oxidative alterations in subjects with schizophrenia under clozapine: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}